ACADIA Pharmaceuticals Inc. (ACAD) Shares: Are They Risky Or Cheap?

0
19
TMC
TMC

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) finished Wednesday with a subtraction of -$1.09 to close at $17.07, a downside of -6.00 percent. An average of 2,128,740 shares of common stock have been traded in the last five days. There was a fall of -$0.36 in the past week, and it reached a new high 21 times over the past 12 months. The last 20 days have seen an average of 1,506,350 shares traded, while the 50-day average volume stands at 1,638,366.

ACAD stock has increased by 1.91% in the last month. The company shares reached their 1-month lowest point of $15.66 on 08/30/22. With the stock rallying to its 52-week high on 04/07/22, shares of the company touched a low of $12.24 and a high of $28.06 in 52 weeks. It has reached a new high 9 times so far this year and lost -26.86% or -$6.27 in price. In spite of this, the price is down -39.16% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Insider Transactions

105 days have passed since ACADIA Pharmaceuticals Inc. (ACAD) last reported insider trading activity. Schneyer Mark C., who is EVP, Chief Financial Officer, most recently acquired $653 shares at $17.91 per share on Jun 09. In this transaction, the insider spent $11,695. CEO, DAVIS STEPHEN, disposed of 5,483 shares at a price of $18.18 on May 02. The insider now owns more than $99,691 worth of shares. Prior to that, President Stankovic Srdjan R. went on to Sale 2,865 shares at $18.18 each on May 02. An amount of $52,091 was transacted.

Valuation Metrics

ACADIA Pharmaceuticals Inc. (ACAD) stock’s beta is 0.64. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.47, the price-to-book (PB) ratio at 6.35.

Financial Health

The quick ratio of ACADIA Pharmaceuticals Inc. for the three months ended June 29 was 4.50, and the current ratio was 4.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $473.3 million compared to revenue of $484.14 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, ACADIA Pharmaceuticals Inc.’s return on assets was -30.80%.

Earnings Surprise

For the three-month period that ended June 29, ACADIA Pharmaceuticals Inc. had $296.52 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$34.01 million in the quarter, while revenues were shrunk -28.99%. The analyst consensus anticipated ACADIA Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.25 per share, but it turned out to be -$0.21, a 16.00% surprise. For the quarter, EBITDA amounted to -$33.04 million. Shareholders own equity worth $161.84 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at ACADIA Pharmaceuticals Inc. (ACAD) price momentum. RSI 9-day as of the close on 21 September was 46.88%, suggesting the stock is Neutral, with historical volatility in this time frame at 57.33%.

As of today, ACAD’s price is $17.88 -2.07% or -$0.36 from its 5-day moving average. ACAD is currently trading +1.13% higher than its 20-day SMA and -10.11% lower than its 100-day SMA. However, the stock’s current price level is +9.92% above the SMA50 and -14.39% below the SMA200.

The stochastic %K and %D were 74.19% and 84.93%, respectively, and the average true range (ATR) was 0.81. With the 14-day stochastic at 44.89% and the average true range at 0.80, the RSI (14) stands at 50.22%. The stock has reached 0.03 on the 9-day MACD Oscillator while the 14-day reading was at 0.34.

Analyst Ratings

Citigroup downgraded ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for ACADIA Pharmaceuticals Inc. (ACAD) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell ACAD, while 12 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.

LEAVE A REPLY

Please enter your comment!
Please enter your name here